Figure 5.
Killing activity of OFA-iLRP-specific CTLs obtained from a patientwith AML. Autologous and allogeneic (AML-1, AML-2, AML-4) OFA-iLRP+ AML blasts were used as targets in a 4-hour 51Chromium release assay.
Killing activity of OFA-iLRP-specific CTLs obtained from a patientwith AML. Autologous and allogeneic (AML-1, AML-2, AML-4) OFA-iLRP+ AML blasts were used as targets in a 4-hour 51Chromium release assay.
